Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial.

MLA

Joharatnam-Hogan, Nalinie, et al. “Thromboxane Biosynthesis in Cancer Patients and Its Inhibition by Aspirin: A Sub-Study of the Add-Aspirin Trial.” British Journal of Cancer, vol. 129, no. 4, Sept. 2023, pp. 706–20. EBSCOhost, https://doi.org/10.1038/s41416-023-02310-1.

APA

Joharatnam-Hogan, N., Hatem, D., Cafferty, F. H., Petrucci, G., Cameron, D. A., Ring, A., Kynaston, H. G., Gilbert, D. C., Wilson, R. H., Hubner, R. A., Swinson, D. E. B., Cleary, S., Robbins, A., MacKenzie, M., Scott-Brown, M. W. G., Sothi, S., Dawson, L. K., Capaldi, L. M., Churn, M., … Langley, R. E. (2023). Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial. British Journal of Cancer, 129(4), 706–720. https://doi.org/10.1038/s41416-023-02310-1

Chicago

Joharatnam-Hogan, Nalinie, Duaa Hatem, Fay H Cafferty, Giovanna Petrucci, David A Cameron, Alistair Ring, Howard G Kynaston, et al. 2023. “Thromboxane Biosynthesis in Cancer Patients and Its Inhibition by Aspirin: A Sub-Study of the Add-Aspirin Trial.” British Journal of Cancer 129 (4): 706–20. doi:10.1038/s41416-023-02310-1.